SIRT6-IN-3

Products

Quote Request

Catalog No.: PC0025

Size: 50 mg, 100mg, 250mg

Description

SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC₅₀=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cell proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) by blocking DNA damage repair pathways. SIRT6-IN-3 for pancreatic cancer research.

Molecular Weight	673.73
Formula	C21H30Br3ClN6S
SMILES	BrC1=C(Br)NC(C2=NC=CC3=C2N=CN3CCCCCCS/C(N(C)C)=[N+](C)\C)=C1.Cl.[Br-]
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
*In Vitro*	SIRT6-IN-3 (25 μM, 48 h) induces PDAC cell-cycle arrest and apoptosis. SIRT6-IN-3 (25 μM, 72 h) inhibits the proliferation of pancreatic cancer cells by inhibiting signaling pathways
*In Vivo*	SIRT6-IN-3 (HY-156027; 20 mg/kg for i.p; once every 2 days for 4 weeks) has antitumor effects on tumor mouse model. SIRT6-IN-3 (HY-156027; 20 mg/kg for i.p; once every 2 days for 4 weeks) enhances the antitumor effects of gemcitabine in vivo when in combination with gemcitabine (ratio 2 : 1)

All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.